[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Evolus Inc (EOLS)

Evolus Inc (EOLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 457,034
  • Shares Outstanding, K 65,855
  • Annual Sales, $ 297,180 K
  • Annual Income, $ -51,640 K
  • EBIT $ -19 M
  • EBITDA $ -9 M
  • 60-Month Beta 1.32
  • Price/Sales 1.55
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 87.13% (+0.96%)
  • Historical Volatility 44.41%
  • IV Percentile 40%
  • IV Rank 9.35%
  • IV High 461.45% on 11/19/25
  • IV Low 48.53% on 08/26/25
  • Expected Move (DTE 9) 0.15 (2.19%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 60
  • Volume Avg (30-Day) 562
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 7,463
  • Open Int (30-Day) 11,333
  • Expected Range 6.84 to 7.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.09
  • Number of Estimates 2
  • High Estimate $-0.07
  • Low Estimate $-0.10
  • Prior Year $-0.30
  • Growth Rate Est. (year over year) +70.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.42 +8.49%
on 06/22/26
7.32 -4.85%
on 06/26/26
+0.29 (+4.27%)
since 06/08/26
3-Month
4.01 +73.47%
on 04/09/26
7.32 -4.85%
on 06/26/26
+2.88 (+70.29%)
since 04/08/26
52-Week
3.86 +80.44%
on 03/30/26
10.20 -31.72%
on 07/24/25
-2.30 (-24.78%)
since 07/08/25

Most Recent Stories

More News
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality

Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an exclusive licensing and...

EOLS : 6.90 (-0.58%)
Evolus to Participate in The Jefferies Global Healthcare Conference

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in...

EOLS : 6.90 (-0.58%)
Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the commercial launch of Estyme ...

EOLS : 6.90 (-0.58%)
Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook

Global Net Revenue of $73.1 Million for the First Quarter of 2026, Up 7% Over the Prior Year and Against the Highest Growth Quarter of 2025 GAAP Operating...

EOLS : 6.90 (-0.58%)
Can Evolus Convince Anyone the Jeuveau Slowdown Is Already Over?

Barchart Research What to Expect from EOLS Earnings EOLS Generated May 1, 2026 Current Price $5.33 EPS Estimate $$-0.22 Consensus Rating Moderate Buy Average Move 14.25% Can Evolus Convince Anyone the...

EOLS : 6.90 (-0.58%)
Can Evolus Convince Anyone the Jeuveau Slowdown Is Already Over?

Barchart Research What to Expect from EOLS Earnings EOLS Generated May 1, 2026 Current Price $5.33 EPS Estimate $$-0.22 Consensus Rating Moderate Buy Average Move 14.25% Can Evolus Convince Anyone the...

EOLS : 6.90 (-0.58%)
Can Evolus Convince Anyone the Jeuveau Slowdown Is Already Over?

Barchart Research What to Expect from EOLS Earnings EOLS Generated May 1, 2026 Current Price $5.33 EPS Estimate $$-0.22 Consensus Rating Moderate Buy Average Move 14.25% Can Evolus Convince Anyone the...

EOLS : 6.90 (-0.58%)
Evolus to Report First Quarter Financial Results on May 4, 2026

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2026 financial...

EOLS : 6.90 (-0.58%)
Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in...

EOLS : 6.90 (-0.58%)
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, Inc. (NASDAQ: EOLS) a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant during March 2026 of an aggregate of 85,516 restricted...

EOLS : 6.90 (-0.58%)

Business Summary

Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus,...

See More

Key Turning Points

3rd Resistance Point 7.27
2nd Resistance Point 7.15
1st Resistance Point 7.05
Last Price 6.90
1st Support Level 6.83
2nd Support Level 6.71
3rd Support Level 6.61

See More

52-Week High 10.20
Fibonacci 61.8% 7.78
Fibonacci 50% 7.03
Last Price 6.90
Fibonacci 38.2% 6.28
52-Week Low 3.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.